290 related articles for article (PubMed ID: 28231581)
1. Prognostic Markers and Histologic Subtypes in Patients with Meningeal Carcinomatosis in Breast Cancer.
Alnajar H; Rosen L; Javidiparsijani S; Al-Ghamdi Y; Gattuso P
Acta Cytol; 2017; 61(2):140-144. PubMed ID: 28231581
[TBL] [Abstract][Full Text] [Related]
2. Comparison of estrogen receptor, progesterone receptor and HER2 results in concurrent ipsilateral samples with invasive breast carcinoma: a retrospective study of 246 biopsies from 119 patients.
Singh K; Wang Y; Marketkar S; Kalife ET; Steinhoff MM
Hum Pathol; 2017 Jul; 65():123-132. PubMed ID: 28457730
[TBL] [Abstract][Full Text] [Related]
3. Keratin 17 is overexpressed and predicts poor survival in estrogen receptor-negative/human epidermal growth factor receptor-2-negative breast cancer.
Merkin RD; Vanner EA; Romeiser JL; Shroyer ALW; Escobar-Hoyos LF; Li J; Powers RS; Burke S; Shroyer KR
Hum Pathol; 2017 Apr; 62():23-32. PubMed ID: 27816721
[TBL] [Abstract][Full Text] [Related]
4. Basal-like immunophenotype markers and prognosis in early breast cancer.
Cassol L; Silveira Graudenz M; Zelmanowicz A; Cancela A; Werutsky G; Rovere RK; Garicochea B
Tumori; 2010; 96(6):966-70. PubMed ID: 21388060
[TBL] [Abstract][Full Text] [Related]
5. Breast cancer leptomeningeal metastasis: propensity of breast cancer subtypes for leptomeninges and the analysis of factors influencing survival.
Niwińska A; Rudnicka H; Murawska M
Med Oncol; 2013 Mar; 30(1):408. PubMed ID: 23322521
[TBL] [Abstract][Full Text] [Related]
6. The maximum standardized uptake value of metastatic site in 18 F-FDG PET/CT predicts molecular subtypes and survival in metastatic breast cancer: An Izmir Oncology Group study.
Cokmert S; Tanriverdi O; Karapolat I; Demir L; Bayoglu V; Can A; Akyol M; Yilmaz Y; Oktay Tarhan M
J BUON; 2016; 21(6):1410-1418. PubMed ID: 28039701
[TBL] [Abstract][Full Text] [Related]
7. Age at diagnosis and distant metastasis in breast cancer--a surprising inverse relationship.
Purushotham A; Shamil E; Cariati M; Agbaje O; Muhidin A; Gillett C; Mera A; Sivanadiyan K; Harries M; Sullivan R; Pinder SE; Garmo H; Holmberg L
Eur J Cancer; 2014 Jul; 50(10):1697-1705. PubMed ID: 24768572
[TBL] [Abstract][Full Text] [Related]
8. How basal are triple-negative breast cancers?
Bertucci F; Finetti P; Cervera N; Esterni B; Hermitte F; Viens P; Birnbaum D
Int J Cancer; 2008 Jul; 123(1):236-40. PubMed ID: 18398844
[TBL] [Abstract][Full Text] [Related]
9. Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers.
Nofech-Mozes S; Trudeau M; Kahn HK; Dent R; Rawlinson E; Sun P; Narod SA; Hanna WM
Breast Cancer Res Treat; 2009 Nov; 118(1):131-7. PubMed ID: 19189211
[TBL] [Abstract][Full Text] [Related]
10. Expression and prognostic significance of ECT2 in invasive breast cancer.
Wang HK; Liang JF; Zheng HX; Xiao H
J Clin Pathol; 2018 May; 71(5):442-445. PubMed ID: 29051317
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
12. Receptor discordance rate and its effects on survival in primary and recurrent breast cancer patients.
Ilgun S; Sarsenov D; Erdogan Z; Ordu C; Celebi F; Nur Pilanci K; Ozturk A; Selamoglu D; Alco G; Aktepe F; Eralp Y; Tuzlali S; Ozmen V
J BUON; 2016; 21(6):1425-1432. PubMed ID: 28039703
[TBL] [Abstract][Full Text] [Related]
13. Negative/low HER2 expression alone or combined with E-cadherin positivity is predictive of better prognosis in patients with breast carcinoma.
Karray-Chouayekh S; Trifa F; Khabir A; Sellami-Boudawara T; Frikha M; Gargouri A; Mokdad-Gargouri R
Histol Histopathol; 2012 Mar; 27(3):377-85. PubMed ID: 22237715
[TBL] [Abstract][Full Text] [Related]
14. Allelic imbalance at the HER2/TOP2A locus in breast cancer.
Huijsmans CJ; van den Brule AJ; Rigter H; Poodt J; van der Linden JC; Savelkoul PH; Hilbink M; Hermans MH
Diagn Pathol; 2015 May; 10():56. PubMed ID: 26022247
[TBL] [Abstract][Full Text] [Related]
15. Metastatic breast carcinoma to the urinary bladder-a report of 11 cases including a tumor to tumor metastasis.
Wang G; Zhou C; Conklin C; Hayes MM; Villamil CF; Ostry A; Jones EC
Virchows Arch; 2019 Mar; 474(3):333-339. PubMed ID: 30607556
[TBL] [Abstract][Full Text] [Related]
16. Lobular breast cancers lack the inverse relationship between ER/PR status and cell growth rate characteristic of ductal cancers in two independent patient cohorts: implications for tumor biology and adjuvant therapy.
Wong H; Lau S; Cheung P; Wong TT; Parker A; Yau T; Epstein RJ
BMC Cancer; 2014 Nov; 14():826. PubMed ID: 25385074
[TBL] [Abstract][Full Text] [Related]
17. High incidence and frequency of LOH are associated with aggressive features of high-grade HER2 and triple-negative breast cancers.
Tokunaga E; Okada S; Yamashita N; Akiyoshi S; Kitao H; Morita M; Kakeji Y; Maehara Y
Breast Cancer; 2012 Apr; 19(2):161-9. PubMed ID: 21063923
[TBL] [Abstract][Full Text] [Related]
18. Meningeal carcinomatosis in breast cancer: prognostic factors and outcome.
de Azevedo CR; Cruz MR; Chinen LT; Peres SV; Peterlevitz MA; de Azevedo Pereira AE; Fanelli MF; Gimenes DL
J Neurooncol; 2011 Sep; 104(2):565-72. PubMed ID: 21234642
[TBL] [Abstract][Full Text] [Related]
19. Survival of breast cancer patients with meningeal carcinomatosis treated by intrathecal thiotepa.
Comte A; Jdid W; Guilhaume MN; Kriegel I; Piperno-Neumann S; Dieras V; Dorval T; Pierga JY; Cottu PH; Mignot L; Bidard FC
J Neurooncol; 2013 Dec; 115(3):445-52. PubMed ID: 24043602
[TBL] [Abstract][Full Text] [Related]
20. Correlation of HER2 overexpression with gene amplification and its relation to chromosome 17 aneuploidy: a 5-year experience with invasive ductal and lobular carcinomas.
Nassar A; Khoor A; Radhakrishnan R; Radhakrishnan A; Cohen C
Int J Clin Exp Pathol; 2014; 7(9):6254-61. PubMed ID: 25337277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
